Who owns Vaxcyte, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PCVX from SEC Form 13F filings across 357 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 357 institutions disclosed 169.9M shares of Vaxcyte, Inc. worth $9.67B — about 114.1% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
357
13F holders
$9.67B
value, 2026 filers
114.1%
of shares outstanding (169.9M sh)
69
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of PCVX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 22.5M | $1.28B | 0.1% | 15.1% | +7.8% |
| 2 | Janus Henderson Group Ltd.NEW | 17.9M | $1.02B | 0.4% | 12% | new |
| 3 | T. Rowe Price Investment Management, Inc. | 14.3M | $813.7M | 0.6% | 9.6% | +17.1% |
| 4 | BlackRock, Inc. | 12.2M | $693.0M | 0.0% | 8.2% | +0.9% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 11.5M | $652.9M | 6.5% | 7.7% | 0.0% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 7.7M | $440.1M | 0.1% | 5.2% | +10.5% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | $373.9M | 0.0% | 4.4% | +3.5% |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $373.8M | 0.0% | 4.4% | -0.4% |
| 9 | STATE STREET CORP | 5.2M | $297.7M | 0.0% | 3.5% | -2.2% |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.5M | $200.9M | 0.0% | 2.4% | +18.1% |
| 11 | Deep Track Capital, LP | 3.5M | $199.9M | 3.3% | 2.4% | -18.3% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $198.9M | 0.0% | 2.3% | +1.0% |
| 13 | WESTFIELD CAPITAL MANAGEMENT CO LP | 3.3M | $186.6M | 0.6% | 2.2% | +32.6% |
| 14 | Kynam Capital Management, LP | 2.6M | $148.4M | 8.2% | 1.8% | -10.8% |
| 15 | GOLDMAN SACHS GROUP INC | 2.3M | $132.7M | 0.0% | 1.6% | +72.7% |
| 16 | Bellevue Group AG | 2.3M | $132.1M | 2.7% | 1.6% | +17.8% |
| 17 | Caligan Partners LP | 2.2M | $124.5M | 7.6% | 1.5% | 0.0% |
| 18 | Paradigm Biocapital Advisors LP | 2.1M | $121.9M | 2.4% | 1.4% | +0.7% |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.7M | $95.7M | 0.0% | 1.1% | +14.9% |
| 20 | D. E. Shaw & Co., Inc. | 1.4M | $81.4M | 0.0% | 1% | -24.7% |
| 21 | Pivotal bioVenture Partners Investment Advisor LLC | 1.4M | $81.1M | 32.2% | 1% | 0.0% |
| 22 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $80.9M | 0.0% | 1% | +19.0% |
| 23 | EVENTIDE ASSET MANAGEMENT, LLC | 1.4M | $78.5M | 1.1% | 0.9% | 0.0% |
| 24 | MAVERICK CAPITAL LTD | 1.4M | $77.4M | 0.6% | 0.9% | -15.7% |
| 25 | NORTHERN TRUST CORP | 1.3M | $72.6M | 0.0% | 0.9% | -0.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.